Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Ex-Pharma Exec Azar Is Top Choice to Run U.S. Health Agency

Yasmeen Abutaleb  |  November 8, 2017

WASHINGTON (Reuters)—Alex Azar, a former pharmaceutical company executive, is U.S. President Donald Trump’s top pick to run the Department of Health and Human Services, two sources with knowledge of the confidential process said on condition of anonymity on Wednesday.

Azar served at Eli Lilly for a decade, including five years as president of its U.S. Lilly USA, LLC unit.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The White House declined to comment.

Tom Price resigned as HHS secretary in September after about seven months in the post, after facing sharp criticism for his use of taxpayer-funded private travel.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Before his stint at Eli Lilly, Azar served as general counsel and deputy secretary for HHS under President George W. Bush.

The new HHS secretary will be tasked with implementing Trump administration efforts to unwind Obamacare, a top campaign promise of his, and overseeing the drug industry, which Trump has said is “getting away with murder” by charging high prices for prescription medications.

Azar has served on the board of directors of the Biotechnology Innovation Organization, a drug industry lobby, for several years, and his nomination would raise questions about the administration’s seriousness about lowering drug prices.

Other names that have been floated to replace Price include Seema Verma, administrator for the Centers for Medicare and Medicaid Services, and Scott Gottlieb, the Food and Drug Administration commissioner.

Republicans control both chambers of Congress and the White House but have repeatedly failed to repeal and replace Obama’s Affordable Care Act, prompting Trump to take steps on his own to dismantle the program.

The Trump administration followed through on a threat to cut off billions of dollars of subsidy payments to insurers, shortened the Obamacare open enrollment period, slashed advertising for the program by 90% and cut funding to groups that help people sign up for health insurance.

In October Trump also signed an executive order that would weaken Obamacare by making it easier for Americans to buy bare-bones health insurance plans.

The administration is already planning changes for 2019. Last month, it proposed a rule giving states more flexibility over the benefits that must be covered by insurance. Under Obamacare, all insurers have to cover a set of 10 benefits, such as maternity and newborn care and prescription drugs.

 

Share: 

Filed under:Professional Topics Tagged with:Alex AzarEli LillyFDA Commissioner Scott GottliebSeema VermaU.S. Department of Health and Human Services

Related Articles

    Trump to Tap Ex-Pharma Executive Azar as U.S. Health Secretary

    November 14, 2017

    WASHINGTON (Reuters)—President Donald Trump on Monday said he will nominate former pharmaceutical executive and industry lobbyist Alex Azar to serve as U.S. Health and Human Services secretary, saying Azar would push to lower the price of medicines. If confirmed, Azar also would take the lead in implementing Trump’s campaign promise to dismantle the Affordable Care…

    Health Secretary Nominee Indicates Support for Medicaid Overhaul

    January 9, 2018

    WASHINGTON (Reuters)—Alex Azar, a former drug industry executive and lobbyist nominated to run the U.S. Department of Health and Human Services, indicated on Tuesday he supported a Republican bid to overhaul Medicaid and again vowed to tackle high drug prices. Azar appeared before the Senate Finance Committee on Tuesday, which will ultimately decide whether to…

    U.S. Senate Committee Advances Azar Nomination as Health Secretary

    January 18, 2018

    WASHINGTON (Reuters)—A U.S. Senate committee on Wednesday voted to move forward the nomination of Alex Azar, a former drug industry executive and lobbyist whom President Donald Trump has tapped to be the next secretary of Health and Human Services. The Senate Finance Committee voted 15-12 to advance Azar’s nomination, with all but one Democrat opposing….

    Some Middle-Class Americans Worry Trump Health Subsidies Cut Will Hurt

    October 19, 2017

    PHILADELPHIA (Reuters)—Tom Westerman voted for Donald Trump in last year’s election but says he might not do so again after the president cut off billions of dollars in Obamacare subsidies to health insurance companies. “It really upset me,” said Westerman, 63, a self-described “middle-class guy” with an annual household income of about $60,000 in the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences